Weekly Gemcitabine Plus Epirubicin for Advanced Pancreatic Cancer
Author Information
Author(s): Neri B, Cini G, Doni L, Fulignati C, Turrini M, Pantalone D, Mini E, De Luca Cardillo C, Fioretto L M, Ribecco A S, Moretti R, Scatizzi M, Zocchi G, Quattrone A
Primary Institution: University of Florence, Italy
Hypothesis
Can the combination of gemcitabine and epirubicin improve treatment outcomes in patients with advanced pancreatic cancer?
Conclusion
The gemcitabine-epirubicin regimen is active and well tolerated in patients with advanced pancreatic cancer, showing a 25% overall response rate and a median survival of 10.9 months.
Supporting Evidence
- 11 patients responded to treatment with one complete response and ten partial responses.
- The median survival duration was 10.9 months.
- 44.4% of eligible patients attained a clinical benefit response.
- Therapy was well tolerated with a low incidence of severe toxicity.
Takeaway
This study tested a new combination of two cancer drugs to see if they could help people with advanced pancreatic cancer feel better and live longer.
Methodology
Patients received epirubicin followed by gemcitabine in a specific schedule, and their responses were assessed for toxicity and effectiveness.
Potential Biases
Potential selection bias due to the eligibility criteria and the multicenter nature of the study.
Limitations
The study had a small sample size and was limited to patients with advanced disease.
Participant Demographics
Median age of participants was 59 years, with most having a Karnofsky performance score of 60 or higher.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI, 19–34%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website